**About PharmaCare**

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

**Details of Drug Reviewed**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Brodalumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand Name</td>
<td>Siliq™</td>
</tr>
<tr>
<td>Dosage Form</td>
<td>Solution for injection</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>Valeant Canada LP</td>
</tr>
<tr>
<td>Submission Type</td>
<td>New Submission</td>
</tr>
<tr>
<td>Use Reviewed</td>
<td>Moderate to severe plaque psoriasis</td>
</tr>
<tr>
<td>Common Drug Review (CDR)</td>
<td>Yes, CDR recommended: <strong>to Reimburse with clinical criteria and/or conditions</strong>. Visit the CDR website for more details: <a href="http://www.cadth.ca/sites/default/files/cdr/complete/SR0547_cdr_complete_Siliq_June_22_18.pdf">www.cadth.ca/sites/default/files/cdr/complete/SR0547_cdr_complete_Siliq_June_22_18.pdf</a></td>
</tr>
</tbody>
</table>

**Provincial Review**

DBC now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry’s drug coverage decision will be based on the CDEC recommendation and an internal review only. The DBC screened brodalumab on February 19, 2018. The DBC advised that because brodalumab is similar to some of the other drugs used for the treatment of moderate to severe plaque psoriasis, the Ministry may proceed its review with CDEC’s recommendation for brodalumab.

**Drug Coverage Decision**

<table>
<thead>
<tr>
<th>Non-Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
</tr>
</tbody>
</table>

**Reasons**

- Drug coverage decision is inconsistent with the CDEC recommendation.
  - The CDEC recommended that brodalumab be listed for the treatment of moderate to severe plaque psoriasis similarly to other biologic drugs for the treatment of psoriasis.
  - CDEC considered three phase 3 double-blind, randomized controlled trials that demonstrated the efficacy of brodalumab in providing statistically significant improvements in skin clearance over the short-term induction phase (12 weeks) compared with placebo.
  - Health Canada- approved brodalumab product monograph contains a boxed Warning about suicidal ideation and behavior, including completed suicides, specifies that patients who are prescribed Siliq are required to enroll in the Siliq Patient Support Program and provide consent that they understand the risks of treatment.
  - The Ministry currently covers a number of medications for psoriasis including biologic medications. Based on British Columbia’s provincial review, brodalumab does not meet any unmet clinical needs and given the short duration of trials, and serious side effects warnings, the clinical benefit of treatment with brodalumab is uncertain.
The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the Drug Benefit Council (DBC) gives advice to the Ministry. The DBC looks at:
- whether the drug is safe and effective
- advice from a national group called the Common Drug Review (CDR)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:
- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the The Drug Review Process in B.C. - Overview and Ministry of Health - PharmaCare for more information.

This document is intended for information only.
It does not take the place of advice from a physician or other qualified health care provider.